Research update · Checked 15 October 2026. These medicines are being investigated for canine longevity. Regulatory milestones are not a guarantee of extra years for an individual dog.
The headline every dog owner wants to believe
If somebody offered us more good years with our dogs, most of us would stop scrolling. More familiar footsteps following us to the kitchen. More walks that take twice as long because the same bush needs another inspection. More of that face at the door.
Scientists are taking that wish seriously. Medicines designed to influence biological ageing are being studied in dogs. The important word is studied: a promising programme is different from a proven promise.
Meet LOY-002
Loyal’s LOY-002 is an investigational daily pill aimed at senior dogs. The company describes its approach as improving metabolic health, including insulin sensitivity, with the goal of preserving quality of life and extending lifespan. It is a drug-development programme, not an ordinary food supplement. See Loyal’s product pipeline.
Loyal reported in January 2026 that the FDA had accepted its target-animal-safety submission, following an earlier reasonable-expectation-of-effectiveness milestone. Its announcement said the manufacturing component remained to be completed, while the placebo-controlled STAY study continued to collect evidence in 1,300 dogs. These are company-reported milestones; they should not be rewritten as “fully approved” or “proven to add two years”. Read the dated safety update. The company’s current site still describes its medicines as products in development.
What does “conditional approval” actually mean?
The FDA explains that conditional approval requires safety and manufacturing standards, but uses a reasonable expectation of effectiveness rather than the substantial evidence required for full approval. If granted, it allows a medicine to be marketed for its labelled use while further effectiveness evidence is gathered. Acceptance of one technical section is not the same thing as granting that conditional approval. See the FDA’s explanation.
Rapamycin is a separate line of research
The Dog Aging Project’s TRIAD trial is testing rapamycin against a placebo in companion dogs, with lifespan and measures of healthy ageing as outcomes. Rapamycin acts on a cellular signalling pathway called mTOR, which helps regulate growth and metabolism. Results in laboratory animals helped motivate this research; they do not establish the same lifespan benefit in pet dogs.
The published TRIAD study-design paper explains what the trial is designed to find out. A study protocol is not a positive results announcement. This is also a different medicine from LOY-002, not another name for the same pill.
More years—or more good years?
Lifespan is how long a dog lives. Healthspan is the period spent in good health and function. For an owner, the meaningful outcome is time a dog can enjoy. A useful treatment would need evidence about benefit, safety and which dogs are likely to benefit—not just a persuasive headline.
What about owners in Dubai and the UAE?
The US developments described here do not establish UAE approval or local availability. We have not verified a UAE-authorised launch for these longevity indications. Ask your licensed vet about current local options and your dog’s individual health before considering any medicine. Do not start rapamycin, import an experimental product or copy a trial dose from the internet without veterinary oversight.
What can we do while the science develops?
Keep their care personal. Discuss body weight, muscle condition, appropriate nutrition, mobility, dental care and changes in behaviour with your vet. The AAHA senior-care guidelines emphasise a tailored healthcare plan; its nutrition guidance considers the needs of the individual ageing pet.
At Nudog, we are interested in the prospect of more happy time together. We will keep the distinction clear: these are emerging medicines, and we are not claiming that Nudog food reproduces their effects or extends lifespan. For now, the research offers a reason to watch carefully—and another reason to appreciate today’s walk.